A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell MalignanciesAlexey V. Danilov, Adrian Wiestner, Michael Tees et al.|Blood|2023Cited by 55
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19Shuchi Gulati, Yu Shyr, Rebecca L. Zon et al.|JAMA Oncology|2023Cited by 10